New oral medicine for active rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a new oral medication, PTC844, for people with active rheumatoid arthritis whose current treatments have not worked well enough or who haven't tried any yet. The goal is to see if it can reduce joint pain and swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a formal diagnosis of rheumatoid arthritis.
- Your RA must be active, meaning you have moderate to severe joint symptoms at the time of screening.
- You cannot have tried any RA disease-modifying drugs, OR if you have tried them, they didn't work well enough or caused too many side effects.
- If you are on background RA treatments, they must have been stable for at least 30 days before the trial starts.
- You must be willing to avoid certain other RA medications during the trial (except for allowed ones like methotrexate, low-dose prednisone, hydroxychloroquine, or sulfasalazine).
- You must not have certain health conditions, such as blood disorders, other inflammatory joint diseases, fibromyalgia, or cancer (except minor skin cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This study tests different targeted treatments for adults with rheumatoid arthritis who have already tried other biologic or targeted medications and need a new option. It aims to find which treatment works best for people like you.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.